The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

BACKGROUND: Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer). This includes site- and time-specific estimates of incidence and efficacy against clinical disease with four different vaccination sched...

Full description

Saved in:
Bibliographic Details
Published in:Malar J
Main Authors: Penny, Melissa A., Pemberton-Ross, Peter, Smith, Thomas A.
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4634589/
https://ncbi.nlm.nih.gov/pubmed/26537608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-015-0969-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items